Welcome to our dedicated page for KYTH news (Ticker: KYTH), a resource for investors and traders seeking the latest updates and insights on KYTH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect KYTH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of KYTH's position in the market.
Sensorion (ARNA) reported full-year 2025 results, provided a corporate update and released its annual report. Key clinical advances include SENS-501 six-month data expected Q1 2026 and SENS-601 (GJB2-GT) CTA submission targeted in H1 2026. The company completed a €60m private placement in Jan 2026, extending cash runway to end of H1 2027.
Financials: 2025 net loss of €29.4m, R&D expenses of €28.8m, and cash & equivalents of €47.5m as of Dec 31, 2025.